|View printer-friendly version|
|Implant Sciences Provides QS-B220 Qualification Testing Update|
Oct 26, 2012 (Marketwire via COMTEX) --Implant Sciences Corporation (
Mr. Glenn Bolduc, President and CEO of Implant Sciences, stated, "As of today, the QS-B220 is with the TSL as part of the independent testing and evaluation process. Independent testing began in early October, after we were notified that we had successfully completed certification readiness. The qualification testing is, by design, an extensive and rigorous process that requires several weeks to complete. We continue to enjoy a strong working relationship with TSL, and have every reason to believe that we will successfully achieve qualification for our QS-B220 trace detector in the near term."
About the Quantum Sniffer™ QS-B220 Handheld Explosives Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact: Implant Sciences Corporation Company Contact: Glenn Bolduc CEO 978-752-1700 Email Contact or Investor Contact: Laurel Moody 646-810-0608 Email Contact